Research programme: anticancer monoclonal antibodies - Meristem TherapeuticsAlternative Names: Monomeric IgA1; Monomeric IgA2; Monomeric IgA3
Latest Information Update: 05 Mar 2013
At a glance
- Originator Meristem Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 24 Feb 2008 No development reported - Preclinical for Cancer in France (Parenteral)
- 24 Feb 2008 No development reported - Preclinical for Cancer in USA (Parenteral)
- 04 Mar 2005 Preclinical trials in Cancer in France (Parenteral)